A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

731

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: JNJ-77242113
DRUG: JNJ-77242113 Matching Placebo
DRUG: Deucravacitinib
DRUG: Deucravacitinib Matching Placebo

Sponsor

Janssen Research & Development, LLC